Home » Stocks » AKER

Akers Biosciences Inc. (AKER)

Stock Price: $2.76 USD 0.07 (2.42%)
Updated Jan 22, 2021 1:00 PM EST - Market open
Market Cap 50.29M
Revenue (ttm) 441,212
Net Income (ttm) -15.63M
Shares Out 7.63M
EPS (ttm) -3.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.76
Previous Close $2.69
Change ($) 0.07
Change (%) 2.42%
Day's Open 2.65
Day's Range 2.61 - 2.77
Day's Volume 84,409
52-Week Range 1.69 - 6.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Akers Biosciences, Inc. (NASDAQ: AKER) conce...

Business Wire - 1 month ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers ...

Business Wire - 1 month ago

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, t...

PRNewsWire - 2 months ago

NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

Business Wire - 2 months ago

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies pl...

PRNewsWire - 2 months ago

BERWYN, Pa., Nov. 17, 2020 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER) re...

PRNewsWire - 2 months ago

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. ("Ake...

PRNewsWire - 2 months ago

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Akers Biosciences, Inc. (NASDAQ: AKER) and its board of directors concerning the...

Business Wire - 2 months ago

BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) today jointly announced that they have entered into a def...

GlobeNewsWire - 4 months ago

Thorofare, New Jersey, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with it...

GlobeNewsWire - 5 months ago

Thorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several i...

GlobeNewsWire - 6 months ago

Company intends to cease focus on screening and testing products business

GlobeNewsWire - 8 months ago

Thorofare, New Jersey, May 18, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the clos...

GlobeNewsWire - 8 months ago

Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it ...

GlobeNewsWire - 8 months ago

Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Pre...

Seeking Alpha - 8 months ago

Akers Biosciences Jumps On COVID-19 Vaccine Progress, Will Remain Volatile

GlobeNewsWire - 9 months ago

Thorofare, New Jersey, April 08, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that i...

GlobeNewsWire - 9 months ago

Thorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that i...

Benzinga - 9 months ago

Akers Biosciences Inc (NASDAQ: AKER) shares gap-opened higher Monday and were trading with handsome gains.

GlobeNewsWire - 9 months ago

Thorofare, New Jersey, April 06, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that i...

GlobeNewsWire - 9 months ago

Thorofare, New Jersey, March 24, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that i...

GlobeNewsWire - 1 year ago

Thorofare, New Jersey, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it...

GlobeNewsWire - 1 year ago

Thorofare, New Jersey, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, announced today that on...

GlobeNewsWire - 1 year ago

Thorofare, New Jersey, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced...

GlobeNewsWire - 1 year ago

Thorofare, New Jersey, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Ex...

GlobeNewsWire - 1 year ago

Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced...

GlobeNewsWire - 1 year ago

· Establishes Advisory Board appointing Bob Hoban and Michael Patterson

GlobeNewsWire - 1 year ago

THOROFARE, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announc...

About AKER

Akers Biosciences focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.

Industry
Medical Instruments & Supplies
Founded
1989
CEO
Howard Yeaton
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
AKER
Full Company Profile

Financial Performance

In 2019, AKER's revenue was $1.58 million, a decrease of -5.32% compared to the previous year's $1.67 million. Losses were -$3.89 million, -64.16% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for AKER is 4.00, which is an increase of 45.19% from the latest price.

Price Target
$4.00
(45.19% upside)